Overview
SCIENTIFIC SCORE
Possibly Effective
Based on 6 Researches
7.3
USERS' SCORE
Good
Based on 5 Reviews
8.6
Supplement Facts
Serving Size: 1 Tablet
Amount Per Serving
%DV
Iron (as Dried Ferrous Sulfate)
45 mg
250%
Top Medical Research Studies
9
Alendronate reduces pain and improves BMD
We explored the effectiveness of alendronate, a common drug for osteoporosis, in treating bone pain and improving bone health in patients with thalassemia. This randomized controlled trial involved men and premenopausal women, who were given either alendronate or a placebo for 12 months.
We found that alendronate significantly improved bone mineral density and reduced back pain. Even better, the treatment was well tolerated with a good safety profile. Overall, our findings suggest that alendronate can be beneficial for those struggling with osteoporosis linked to thalassemia.
We found that alendronate significantly improved bone mineral density and reduced back pain. Even better, the treatment was well tolerated with a good safety profile. Overall, our findings suggest that alendronate can be beneficial for those struggling with osteoporosis linked to thalassemia.
8
We examined a case of a 32-year-old woman on long-term hemodialysis who experienced severe bone pain and fractures. Initial tests showed high levels of iron and aluminum. After treating her with deferoxamine—a chelating agent—her bone pain improved, and a follow-up biopsy showed better bone health. However, while her pain was managed, her iron and aluminum levels changed only slightly, highlighting the complexity of treating conditions linked to metal imbalances.
8
We explored how cancer in the bones, specifically from breast tumors, leads to severe pain due to increased levels of glutamate. In our research, we found that certain chemicals, including iron-based compounds, can reduce this glutamate release. This reduction helps alleviate pain symptoms in models of cancer-induced bone pain. While our findings suggest that targeting the glutamate pathway may be effective, we did not find that iron treatment alone significantly impacts bone pain management. Overall, this study highlights potential new avenues for treating pain associated with bone metastases.
Most Useful Reviews
9
Reduced bone pain
89 people found this helpful
I ordered vitamin 31 recently, and my life has improved significantly. I’ve lost around 6 pounds, and my appetite is better. I can now sleep comfortably at night without all the bone pain. Vitamin 31 has alleviated my chronic pain from sciatica and other health issues. Thank you, Dr. Clemens.
9
No gastritis pain
4 people found this helpful
This iron quickly raised my haemoglobin. Previously, the medications I tried caused strong gastritis attacks. I decided to order this iron, and it was the right choice! I took it on an empty stomach without pain, and it quickly improved my haemoglobin. Now, my friends praise it.
9
Effective for haemoglobin
I liked the slow-release iron. It didn’t cause abdominal pain, and my haemoglobin levels have risen. I would highly recommend it.
Medical Researches
SCIENTIFIC SCORE
Possibly Effective
Based on 6 Researches
7.3
- All Researches
9
Alendronate reduces pain and improves BMD
We explored the effectiveness of alendronate, a common drug for osteoporosis, in treating bone pain and improving bone health in patients with thalassemia. This randomized controlled trial involved men and premenopausal women, who were given either alendronate or a placebo for 12 months.
We found that alendronate significantly improved bone mineral density and reduced back pain. Even better, the treatment was well tolerated with a good safety profile. Overall, our findings suggest that alendronate can be beneficial for those struggling with osteoporosis linked to thalassemia.
We found that alendronate significantly improved bone mineral density and reduced back pain. Even better, the treatment was well tolerated with a good safety profile. Overall, our findings suggest that alendronate can be beneficial for those struggling with osteoporosis linked to thalassemia.
8
We explored how cancer in the bones, specifically from breast tumors, leads to severe pain due to increased levels of glutamate. In our research, we found that certain chemicals, including iron-based compounds, can reduce this glutamate release. This reduction helps alleviate pain symptoms in models of cancer-induced bone pain. While our findings suggest that targeting the glutamate pathway may be effective, we did not find that iron treatment alone significantly impacts bone pain management. Overall, this study highlights potential new avenues for treating pain associated with bone metastases.
8
We examined a case of a 32-year-old woman on long-term hemodialysis who experienced severe bone pain and fractures. Initial tests showed high levels of iron and aluminum. After treating her with deferoxamine—a chelating agent—her bone pain improved, and a follow-up biopsy showed better bone health. However, while her pain was managed, her iron and aluminum levels changed only slightly, highlighting the complexity of treating conditions linked to metal imbalances.
7
We examined the long-term safety and effectiveness of luspatercept in adult patients with β-thalassemia, a genetic blood disorder that leads to anemia. The study involved a diverse group of 64 patients, analyzing how well luspatercept could help increase hemoglobin levels and reduce blood transfusions over an extended period.
Importantly, while luspatercept showed significant benefits, common side effects included mild headaches and bone pain. However, these symptoms did not emerge as major concerns, and patients reported manageable experiences overall.
Our findings suggest luspatercept can be a valuable treatment for both transfusion-dependent and nontransfusion-dependent β-thalassemia patients.
Importantly, while luspatercept showed significant benefits, common side effects included mild headaches and bone pain. However, these symptoms did not emerge as major concerns, and patients reported manageable experiences overall.
Our findings suggest luspatercept can be a valuable treatment for both transfusion-dependent and nontransfusion-dependent β-thalassemia patients.
7
We explored the connection between bone pain and iron treatment in patients on maintenance hemodialysis. In our observation, two patients suffered from bone pain related to aluminum and iron-related bone disease, which was alleviated by deferoxamine therapy.
However, we also noted that three patients experienced transverse fractures under normal daily activities. This indicates that both aluminum and iron-related diseases can weaken bone, leading to fractures even with minimal stress.
However, we also noted that three patients experienced transverse fractures under normal daily activities. This indicates that both aluminum and iron-related diseases can weaken bone, leading to fractures even with minimal stress.
User Reviews
USERS' SCORE
Good
Based on 5 Reviews
8.6
- All Reviews
- Positive Reviews
- Negative Reviews
9
Reduced bone pain
89 people found this helpful
I ordered vitamin 31 recently, and my life has improved significantly. I’ve lost around 6 pounds, and my appetite is better. I can now sleep comfortably at night without all the bone pain. Vitamin 31 has alleviated my chronic pain from sciatica and other health issues. Thank you, Dr. Clemens.
9
No gastritis pain
4 people found this helpful
This iron quickly raised my haemoglobin. Previously, the medications I tried caused strong gastritis attacks. I decided to order this iron, and it was the right choice! I took it on an empty stomach without pain, and it quickly improved my haemoglobin. Now, my friends praise it.
9
Effective for haemoglobin
I liked the slow-release iron. It didn’t cause abdominal pain, and my haemoglobin levels have risen. I would highly recommend it.
7.5
Improved stomach issues
7 people found this helpful
My stomach isn’t bothering me, and the iron doesn’t cause pain, but it was acceptable. My anaemia has improved. The tablet is small and easy to swallow, although it is a frustrating dark red colour. I struggle to open the child-lock lid.
7.5
Mild side effects
2 people found this helpful
I chose a slow-release iron as it has lighter side effects than standard iron. I recommend it to anyone who struggles with side effects like nausea, stomach pain, or constipation.
Frequently Asked Questions
9
Reduced bone pain
89 people found this helpful
I ordered vitamin 31 recently, and my life has improved significantly. I’ve lost around 6 pounds, and my appetite is better. I can now sleep comfortably at night without all the bone pain. Vitamin 31 has alleviated my chronic pain from sciatica and other health issues. Thank you, Dr. Clemens.
9
Effective for haemoglobin
I liked the slow-release iron. It didn’t cause abdominal pain, and my haemoglobin levels have risen. I would highly recommend it.
7.5
Mild side effects
2 people found this helpful
I chose a slow-release iron as it has lighter side effects than standard iron. I recommend it to anyone who struggles with side effects like nausea, stomach pain, or constipation.
9
No gastritis pain
4 people found this helpful
This iron quickly raised my haemoglobin. Previously, the medications I tried caused strong gastritis attacks. I decided to order this iron, and it was the right choice! I took it on an empty stomach without pain, and it quickly improved my haemoglobin. Now, my friends praise it.
7.5
Improved stomach issues
7 people found this helpful
My stomach isn’t bothering me, and the iron doesn’t cause pain, but it was acceptable. My anaemia has improved. The tablet is small and easy to swallow, although it is a frustrating dark red colour. I struggle to open the child-lock lid.
9
Alendronate reduces pain and improves BMD
We explored the effectiveness of alendronate, a common drug for osteoporosis, in treating bone pain and improving bone health in patients with thalassemia. This randomized controlled trial involved men and premenopausal women, who were given either alendronate or a placebo for 12 months.
We found that alendronate significantly improved bone mineral density and reduced back pain. Even better, the treatment was well tolerated with a good safety profile. Overall, our findings suggest that alendronate can be beneficial for those struggling with osteoporosis linked to thalassemia.
We found that alendronate significantly improved bone mineral density and reduced back pain. Even better, the treatment was well tolerated with a good safety profile. Overall, our findings suggest that alendronate can be beneficial for those struggling with osteoporosis linked to thalassemia.
5
We reviewed various treatments for osteoporosis in individuals with beta-thalassemia to see how they alleviate bone pain. Among the treatments, bisphosphonates showed potential for increasing bone density, while zinc supplementation was likely to enhance site-specific bone mass.
Notably, denosumab and strontium ranelate appeared to significantly reduce bone pain measured on a scale, indicating improved quality of life. However, the overall evidence certainty was low, emphasizing a need for more extensive trials. There's promise, but further research is essential to draw firmer conclusions.
Notably, denosumab and strontium ranelate appeared to significantly reduce bone pain measured on a scale, indicating improved quality of life. However, the overall evidence certainty was low, emphasizing a need for more extensive trials. There's promise, but further research is essential to draw firmer conclusions.
8
We examined a case of a 32-year-old woman on long-term hemodialysis who experienced severe bone pain and fractures. Initial tests showed high levels of iron and aluminum. After treating her with deferoxamine—a chelating agent—her bone pain improved, and a follow-up biopsy showed better bone health. However, while her pain was managed, her iron and aluminum levels changed only slightly, highlighting the complexity of treating conditions linked to metal imbalances.
7
We explored the connection between bone pain and iron treatment in patients on maintenance hemodialysis. In our observation, two patients suffered from bone pain related to aluminum and iron-related bone disease, which was alleviated by deferoxamine therapy.
However, we also noted that three patients experienced transverse fractures under normal daily activities. This indicates that both aluminum and iron-related diseases can weaken bone, leading to fractures even with minimal stress.
However, we also noted that three patients experienced transverse fractures under normal daily activities. This indicates that both aluminum and iron-related diseases can weaken bone, leading to fractures even with minimal stress.
8
We explored how cancer in the bones, specifically from breast tumors, leads to severe pain due to increased levels of glutamate. In our research, we found that certain chemicals, including iron-based compounds, can reduce this glutamate release. This reduction helps alleviate pain symptoms in models of cancer-induced bone pain. While our findings suggest that targeting the glutamate pathway may be effective, we did not find that iron treatment alone significantly impacts bone pain management. Overall, this study highlights potential new avenues for treating pain associated with bone metastases.
References
- Piriyakhuntorn P, Tantiworawit A, Phimphilai M, Srichairatanakool S, Teeyasoontranon W, et al. The efficacy of alendronate for the treatment of thalassemia-associated osteoporosis: a randomized controlled trial. Front Endocrinol (Lausanne). 2023;14:1178761. doi:10.3389/fendo.2023.1178761
- Bhardwaj A, Swe KMM, Sinha NK. Treatment for osteoporosis in people with beta-thalassaemia. Cochrane Database Syst Rev. 2023;5:CD010429. doi:10.1002/14651858.CD010429.pub3
- Piga A, Longo F, Gamberini MR, Voskaridou E, Ricchi P, et al. Long-term safety and erythroid response with luspatercept treatment in patients with β-thalassemia. Ther Adv Hematol. 2022;13:20406207221134404. doi:10.1177/20406207221134404
- Slosky LM, BassiriRad NM, Symons AM, Thompson M, Doyle T, et al. The cystine/glutamate antiporter system xc- drives breast tumor cell glutamate release and cancer-induced bone pain. Pain. 2016;157:2605. doi:10.1097/j.pain.0000000000000681
- Yamagata K, Kobayashi M, Koyama A, Narita M, Amagai H, et al. [A case of iron and aluminum related osteomalacia in a long-term hemodialysis patient]. Nihon Jinzo Gakkai Shi. 1991;33:437.
- Marumo F, Nomura T, Nishikawa H. Transverse fractures of the spinous process of the 7th cervical vertebra in RDT patients: an Al related disease?. Int J Artif Organs. 1987;10:93.
